Labcorp stock gains after Q2 2026 results and raised guidance

Labcorp stock (ISIN US50540R4092) closed at USD 323.97 on the New York Stock Exchange on September 15, 2026, up 2.75 percent from the prior close of around USD 315.31 after investors digested fresh Q2 2026 figures and updated guidance.

Q2 2026 results and guidance update

According to an overview of testing and diagnostics services stocks from Yahoo Finance on September 16, 2026, Labcorp reported Q2 2026 revenues of USD 3.73 billion, an increase of 5.8 percent year on year and broadly in line with analysts' expectations for the quarter.

The same analysis notes that Labcorp generated earnings of USD 298.7 million in Q2 2026, corresponding to a profit margin of 8.01 percent for the period ended June 30, 2026, giving investors a clearer picture of the company’s profitability in its core testing and diagnostics businesses.Yahoo Finance

As detailed in the earnings history tables for Labcorp on Yahoo Finance, adjusted EPS for Q2 2026 came in at USD 4.99 compared with a consensus estimate of USD 4.77, representing a positive surprise of 0.22 dollars or 4.65 percent and marking an acceleration from year-ago EPS of USD 4.18.

A German-language analysis from IT BOLTWISE on September 17, 2026 highlights that Labcorp paired its Q2 2026 results with a raised outlook, lifting its full-year 2026 guidance for adjusted EPS to a range of USD 18.10 to USD 18.55, compared with prior expectations around USD 18 and signaling management’s confidence that earnings can grow by roughly 11.2 percent from the 2025 level of USD 16.44.

In the same commentary, IT BOLTWISE notes that Labcorp now anticipates revenue growth between 5 and 8 percent for fiscal year 2026, providing a corridor that frames the 5.8 percent year-on-year increase in Q2 2026 as broadly consistent with the company’s full-year growth ambitions.IT BOLTWISE

Analyst reaction and valuation backdrop

The Q2 2026 release and guidance update prompted a fresh look from analysts at the stock’s valuation. IT BOLTWISE reports that UBS recently reaffirmed its Buy rating on Labcorp and raised its 12-month price target from USD 361 to USD 380, implying an increase of USD 19 or 5.3 percent in the target and a potential upside of about 17 percent from the September 15, 2026 closing price of USD 323.97.IT BOLTWISE

For investors comparing Labcorp with other testing and diagnostics peers, the sector benchmarking on Yahoo Finance points out that, despite Labcorp’s Q2 2026 EPS beat and guidance lift, the company delivered the slowest revenue growth and weakest full-year guidance update among the group, underscoring that its premium valuation depends on sustained margin improvement rather than top-line acceleration alone.

That same sector piece notes that Labcorp shares have risen 7.6 percent since the Q2 2026 results were released and recently traded around USD 330.36, a move that outpaces the broader diagnostics cohort and leaves the stock on a higher earnings multiple that investors will continue to gauge against the company’s ability to deliver on its profit margin targets.Yahoo Finance

The IT BOLTWISE coverage further highlights that Labcorp’s year-to-date total return stands at 30.09 percent for 2026, compared with a 10.81 percent gain for the S&P 500 Index over the same period, meaning the stock has outperformed the broader US market by about 19.28 percentage points as investors have rewarded the company’s execution and updated guidance.IT BOLTWISE

Stock performance and market context

In a broader market environment where the Dow Jones Industrial Average fell about 1.2 percent on September 15, 2026 and the S&P 500 declined 0.69 percent as investors reacted to a hawkish Federal Reserve rate decision, Labcorp’s 2.75 percent gain on the day stands out as a clear outperformance against the major indices.Ad-hoc-newsMoneycontrol

An article summarizing market data for Labcorp on September 17, 2026 notes that the stock ended the September 15, 2026 session at USD 323.97 after trading between an intraday low near USD 319 and a high around USD 325, keeping the close within the day’s range and pointing to a relatively stable intraday pattern despite the broader market volatility.Ad-hoc-news

IT BOLTWISE points out that, immediately after the Q2 2026 numbers were made public, Labcorp shares climbed by 7.6 percent in a short period and were at times quoted around USD 330.36, suggesting that the market reaction to the earnings beat and guidance lift was swift and that the stock has since consolidated slightly below that post-results peak.IT BOLTWISE

Closing price and investor view

Labcorp stock is referenced with a New York Stock Exchange closing price of USD 323.97 as of September 15, 2026, providing investors with a recent benchmark for the shares in the wake of the Q2 2026 earnings beat and raised full-year guidance.

More news and analyses on Labcorp stock